Drugs / Selnoflast
Selnoflast
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05924243 | Sep 2022 → Jul 2024 | Parkinson disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04086602 | Sep 2019 → Feb 2020 | cryopyrin-associated periodic syndrome | Inflazome UK Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07448038 | Jun 2026 → Jan 2028 expected | atherosclerosis | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selnoflast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07448038 ↗ |
| Known as | IZD334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04086602 ↗ |
| Known as | RO-7486967 POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095423 ↗ |
| Known as | RO7486967 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05924243 ↗ |
| Known as | SELNOFLAST POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095423 ↗ |
| Modality | Small molecule | — CHEMBL5095423 ↗ |
| Route | Oral | “Once daily oral IZD334 or Placebo” NCT04086602 ↗ |